WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a cli

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra

Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and rai

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and ra

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a cli

Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform

Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's r

Disc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3

Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and second

Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-d

Disc Medicine (IRON) is experiencing a significant surge today following the announcement of positiv

Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co

Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-st

Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on M

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight

U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout,

U.S. stock futures were higher on Monday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose,

Disc Medicine's rare disease drug succeeds in late-stage trial

Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-

Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningf

XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 reven

WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-st

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor righ

New York, New York--(Newsfile Corp. - October 6, 2026) - WHY: Rosen Law Firm, a global investor righ

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor righ

New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor righ

NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues

New York, New York--(Newsfile Corp. - September 30, 2026) - WHY: Rosen Law Firm, a global investor r

New York, New York--(Newsfile Corp. - September 29, 2026) - WHY: Rosen Law Firm, a global investor r

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai

Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hem

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and ra

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.54) per share which beat the analyst co

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

Consistent, substantial decreases in hepcidin reaching >75% reduction from baseline and correspon

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra

https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm